{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:28Z","timestamp":1793640688914,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41434-025-00589-8","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T17:42:52Z","timestamp":1767807772000},"page":"266-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metadata assessment of non-human primate studies of AAV9 uncovers potential tissue specific variation in expression efficiency"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0224-0373","authenticated-orcid":false,"given":"Muhammad","family":"Shahrukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2948-2370","authenticated-orcid":false,"given":"Julianne R.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Ozsolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","volume":"38","author":"F Testa","year":"2024","unstructured":"Testa F, Bacci G, Falsini B, Iarossi G, Melillo P, Mucciolo DP, et al. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye. 2024;38:2504\u201315.","journal-title":"Eye"},{"key":"589_CR2","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide T, Rathore R, Rangrej SB, Hutchinson S, Lewis M, Ojilere S, et al. Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus. 2023;15:e36197.","journal-title":"Cureus"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","volume":"39","author":"J Shah","year":"2022","unstructured":"Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Mes Res Opin. 2022;39:227\u201337.","journal-title":"Curr Mes Res Opin"},{"key":"589_CR4","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fern\u00e1ndez A, Low SH, Fran\u00e7ois A, Su\u00e1rez-Amar\u00e1n L, Samulksi RJ. AAV vectors: The Rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30:3515\u201341.","journal-title":"Mol Ther"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/0192623318803867","volume":"46","author":"BT Assaf","year":"2018","unstructured":"Assaf BT, Whiteley LO. Considerations for preclinical safety assessment of adeno-associated virus gene therapy products. Toxicol Pathol. 2018;46:1020\u20137.","journal-title":"Toxicol Pathol"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/mt.2010.234","volume":"19","author":"H Petrs-Silva","year":"2011","unstructured":"Petrs-Silva H, Dinculescu A, Li Q, Deng W, Pang J, Min S, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2011;19:293\u2013301.","journal-title":"Mol Ther"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3893","volume":"49","author":"G Logan","year":"2017","unstructured":"Logan G, Dane A, Hallwirth C, Smyth CM, Wilkie EE, Amaya AK, et al. Identification of liver-specific enhancer\u2013promoter activity in the 3\u2032 untranslated region of the wild-type AAV2 genome. Nat Genet. 2017;49:1267\u201373.","journal-title":"Nat Genet"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/hum.2005.16.235","volume":"16","author":"S Chen","year":"2005","unstructured":"Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM, et al. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther. 2005;16:235\u201347.","journal-title":"Hum Gene Ther"},{"key":"589_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41434-020-0178-0","volume":"28","author":"KL Pietersz","year":"2021","unstructured":"Pietersz KL, Martier RM, Baatje MS, Liefhebber JM, Brouwers CC, Pouw SM, et al. Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. 2021;28:435\u201346.","journal-title":"Gene Ther"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2119\/molmed.2012.00299","volume":"18","author":"RA Charan","year":"2012","unstructured":"Charan RA, Niizawa G, Nakai H, Clemens PR. Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-\u03baB in muscle of mdx mice. Mol Med. 2012;18:1527\u201335.","journal-title":"Mol Med"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40291-020-00467-6","volume":"24","author":"JD Rubin","year":"2020","unstructured":"Rubin JD, Barry MA. Improving molecular therapy in the kidney. Mol Diagn Ther. 2020;24:375\u201396.","journal-title":"Mol Diagn Ther"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13861","volume":"140","author":"SF Merkel","year":"2017","unstructured":"Merkel SF, Andrews AM, Lutton EM, Mu D, Hudry E, Hyman BT, et al. Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. J Neurochem. 2017;140:216\u201330.","journal-title":"J Neurochem"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","volume":"241","author":"J Saraiva","year":"2016","unstructured":"Saraiva J, Nobre RJ, Pereira de Almeida L. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J Control Release. 2016;241:94\u2013109.","journal-title":"J Control Release"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","volume":"355","author":"L Kang","year":"2023","unstructured":"Kang L, Jin S, Wang J, Lv Z, Xin C, Tan C, et al. AAV vectors applied to the treatment of CNS disorders: clinical status and challenges. J Control Release. 2023;355:458\u201373.","journal-title":"J Control Release"},{"key":"589_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101434","volume":"33","author":"K Fang","year":"2025","unstructured":"Fang K, Yang X, Liu Y, Xia J, Wu R, Yang F, et al. A comprehensive study of AAV tropism across C57BL\/6 mice, BALB\/c mice, and crab-eating macaques. Mol Ther Methods Clin Dev. 2025;33:101434.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"589_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109777","volume":"27","author":"SG Giannelli","year":"2024","unstructured":"Giannelli SG, Luoni M, Iannielli A, Middeldorp J, Philippens I, Bido S, et al. New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets. iScience. 2024;27:109777.","journal-title":"iScience"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.ymthe.2023.07.020","volume":"31","author":"E Hudry","year":"2023","unstructured":"Hudry E, Aihara F, Meseck E, Mansfield K, McElroy C, Chand D, et al. Liver injury in cynomolgus monkeys following intravenous and intrathecal SCAAV9 gene therapy delivery. Mol Ther. 2023;31:2999\u20133014.","journal-title":"Mol Ther"},{"key":"589_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.51","volume":"1","author":"C Hinderer","year":"2014","unstructured":"Hinderer C, Bell P, Vite CH, Louboutin JP, Grant R, Bote E, et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev. 2014;1:14051.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/01926233221101309","volume":"50","author":"EK Meseck","year":"2022","unstructured":"Meseck EK, Guibinga G, Wang S, McElroy C, Hudry E, Mansfield K. Intrathecal sc-AAV9-CB-GFP: systemic distribution predominates following single-dose administration in cynomolgus macaques. Toxicol Pathol. 2022;50:415\u201331.","journal-title":"Toxicol Pathol"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/hum.2021.255","volume":"33","author":"FF Tukov","year":"2022","unstructured":"Tukov FF, Mansfield K, Milton M, Meseck E, Penraat K, Chand D, et al. Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys. Hum Gene Ther. 2022;33:740\u201356.","journal-title":"Hum Gene Ther"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","volume":"42","author":"JA Greig","year":"2023","unstructured":"Greig JA, Martins KM, Breton C, Lamontagne RJ, Zhu Y, He Z, et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol. 2023;42:1232\u201342.","journal-title":"Nat Biotechnol"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2005.07.015","volume":"86","author":"N Brunetti-Pierri","year":"2005","unstructured":"Brunetti-Pierri N, Lee B. Gene Therapy for inborn errors of liver metabolism. Mol Genet Metab. 2005;86:13\u201324.","journal-title":"Mol Genet Metab"},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994\u20132004.","journal-title":"N Engl J Med"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ymthe.2025.03.041","volume":"33","author":"F Puzzo","year":"2025","unstructured":"Puzzo F, Kay MA. The delivered promises of gene therapy: past, present, and future of liver-directed gene therapy. Mol Ther. 2025;33:1966\u201387.","journal-title":"Mol Ther"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jimd.12637","volume":"47","author":"MA Chuecos","year":"2024","unstructured":"Chuecos MA, Lagor WR. Liver directed adeno-associated viral vectors to treat metabolic disease. J Inherit Metab Dis. 2024;47:22\u201340.","journal-title":"J Inherit Metab Dis"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/hum.2024.179","volume":"36","author":"P Piccolo","year":"2025","unstructured":"Piccolo P, Brunetti-Pierri N. Current and emerging issues in adeno-associated virus vector-mediated liver-directed gene therapy. Hum Gene Ther. 2025;36:77\u201387.","journal-title":"Hum Gene Ther"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/mthe.2001.0442","volume":"4","author":"RW Herzog","year":"2001","unstructured":"Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4:192\u2013200.","journal-title":"Mol Ther"},{"key":"589_CR28","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","volume":"72","author":"D Duan","year":"1998","unstructured":"Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72:8568\u201377.","journal-title":"J Virol"},{"key":"589_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101409","volume":"33","author":"M Journou","year":"2025","unstructured":"Journou M, Devaux M, Jaulin N, Pichard V, Segovia M, Moreau A, et al. Immune-driven gene expression loss following intramuscular AAV delivery to non-human primates is only transient. Mol Ther Methods Clin Dev. 2025;33:101409.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","volume":"159","author":"S Lang","year":"2020","unstructured":"Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020;159:1839\u201352.","journal-title":"Gastroenterology"},{"key":"589_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104113","volume":"81","author":"Z Cao","year":"2022","unstructured":"Cao Z, Sugimura N, Burgermeister E, Ebert MP, Zuo T, Lan P. The gut virome: a new microbiome component in health and disease. EBioMedicine. 2022;81:104113.","journal-title":"EBioMedicine"},{"key":"589_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02039-21","volume":"96","author":"A Das","year":"2022","unstructured":"Das A, Vijayan M, Walton EM, Stafford VG, Fiflis DN, Asokan A. Epigenetic silencing of recombinant adeno-associated virus genomes by NP220 and the HUSH complex. J Virol. 2022;96:e0203921.","journal-title":"J Virol"},{"key":"589_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38106-3","volume":"14","author":"A Gonzalez-Sandoval","year":"2023","unstructured":"Gonzalez-Sandoval A, Pekrun K, Tsuji S, Zhang F, Hung KL, Chang HY, et al. The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner. Nat Commun. 2023;14:2448.","journal-title":"Nat Commun"},{"key":"589_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32978-7","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Fan R, Russo A, Cernilogar FM, Number A, Schirge S, et al. Dominant role of DNA methylation over H3K9me3 for IAP silencing in endoderm. Nat Commun. 2022;13:5447.","journal-title":"Nat Commun"},{"key":"589_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20940-y","volume":"12","author":"Y Cai","year":"2021","unstructured":"Cai Y, Zhang Y, Loh YP, Tng JQ, Lim MC, Cao Z, et al. H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions. Nat Commun. 2021;12:719.","journal-title":"Nat Commun"},{"key":"589_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315\u201326.","journal-title":"Cell"},{"key":"589_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/hum.2021.116","volume":"33","author":"X Palazzi","year":"2022","unstructured":"Palazzi X, Pardo ID, Sirivelu MP, Newman L, Kumpf SW, Qian J, et al. Biodistribution and tolerability of AAV-PHP.B-CBh-SMN1 in Wistar Han rats and cynomolgus macaques reveal different toxicologic profiles. Hum Gene Ther. 2022;33:175\u201387.","journal-title":"Hum Gene Ther"},{"key":"589_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa2214084","volume":"389","author":"L D\u2019Antiga","year":"2023","unstructured":"D\u2019Antiga L, Beuers U, Ronzitti G, Brunetti-Pierri N, Baumann U, Di Giorgio A, et al. Gene therapy in patients with the Crigler\u2013Najjar syndrome. N Engl J Med. 2023;389:620\u201331.","journal-title":"N Engl J Med"},{"key":"589_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ymthe.2005.11.010","volume":"13","author":"T Okada","year":"2006","unstructured":"Okada T, Uchibori R, Iwata-Okada M, Takahashi M, Nomoto T, Nonaka-Sarukawa M, et al. A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther. 2006;13:738\u201346.","journal-title":"Mol Ther"},{"key":"589_CR40","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals. 2010;3:2751\u201367.","journal-title":"Pharmaceuticals"},{"key":"589_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jviromet.2004.11.023","volume":"125","author":"S Fan","year":"2005","unstructured":"Fan S, Maguire CA, Ramirez SH, Bradel-Tretheway B, Sapinoro R, Sui Z, et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods. 2005;125:23\u201333.","journal-title":"J Virol Methods"},{"key":"589_CR42","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.7150\/thno.108593","volume":"15","author":"X He","year":"2025","unstructured":"He X, Yuan R, Chen Y, Huang W, Xu Z, Wang B, et al. Mechanism of valproic acid-induced hepatic steatosis via enhancing NRF2-FATP2-mediated fatty acid uptake. Theranostics. 2025;15:5258\u201376.","journal-title":"Theranostics"},{"key":"589_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/genes8090232","volume":"8","author":"D Chanda","year":"2017","unstructured":"Chanda D, Hensel JA, Higgs JT, Grover R, Kaza N, Ponnazhagan S. Effects of cellular methylation on transgene expression and site-specific integration of adeno-associated virus. Genes. 2017;8:232.","journal-title":"Genes"},{"key":"589_CR44","doi-asserted-by":"publisher","unstructured":"Subkhankulova EO, Tolmachov T. Silencing of transgene expression: a gene therapy perspective. Gene Ther. Tools Potential Appl. https:\/\/doi.org\/10.5772\/53379 (2013).","DOI":"10.5772\/53379"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00589-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:02:44Z","timestamp":1780326164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00589-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00589-8","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S., J.R.S., T.d.R., and F.O. are all employees of Novartis Biomedical Research. All authors own Novartis stock or other equities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}